Collegium Pharmaceutical, Inc. (COLL) Q2 2021 Earnings Results

Collegium Pharmaceutical Beats on EPS, Stock Down 0.4%

Collegium Pharmaceutical reported a strong earnings per share, significantly exceeding expectations. However, the stock reacted negatively, declining by 0.4%. This may indicate that investors were looking for more comprehensive guidance or revenue details, which were not provided.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.79	N/A	+434.33%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Unknown

No transcript is on record for the earnings call, so the analysis is based solely on numerical results.

Collegium Pharmaceutical Beats on EPS, Stock Down 0.4%

Key numbers

Management commentary

Collegium Pharmaceutical, Inc.

More earnings this week

Collegium Pharmaceutical Beats on EPS, Stock Down 0.4%

Key numbers

Management commentary